Clinical Combo Trial Recruiting

This moderated forum is to support the needs of patients with stage III melanoma, as well as to answer questions about treatment options and what to expect.

Clinical Combo Trial Recruiting

Postby Catherine Poole » Tue Oct 17, 2017 9:59 am

A Phase 2 clinical trial called IMO-2125-204, NCT02644967, for the treatment of patients with advanced melanoma. The IMO-2125-204 clinical trial will evaluate the treatment of IMO-2125 (an investigational drug) in combination with either ipilimumab (Yervoy®) or pembrolizumab (Keytruda®). If you, or someone you know, has been diagnosed with an advanced form of metastatic melanoma (melanoma that has spread to other parts of the body) for whom treatment has failed with Keytruda® (pembrolizumab) or Opdivo® (nivolumab), you may be eligible to participate in the IMO-2125-204 clinical trial. For more information about the trial,

please visit clinicaltrials.gov/NCT02644967
Catherine M. Poole, President/Founder
Melanoma International Foundation
Catherine Poole
 
Posts: 10782
Joined: Wed Jan 02, 2008 12:09 am

Return to Melanoma: Stage III

Who is online

Registered users: Bing [Bot], Google [Bot]